SCHEMBL19739949

SCHEMBL19739949

COCc1ccc2cc(C(=O)NC3C4CCN(CC4)C34CC4)sc2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ CHRNA7 P36544 20/20 1.00
▸ HTR3A P46098 6/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19740369 1.00 CHRNA7 (1.00) CHRNA7HTR3A
SCHEMBL19740219 1.00 CHRNA7 (1.00) CHRNA7HTR3A
Hydrochloric Acid SCHEMBL19740236 0.99 CHRNA7 (0.98) CHRNA7HTR3A
SCHEMBL19740003 0.90 CHRNA7 (0.82) CHRNA7HTR3A
SCHEMBL17843097 0.90 CHRNA7 (0.82) CHRNA7HTR3A
SCHEMBL19740389 0.90 CHRNA7 (0.82) CHRNA7HTR3A
Hydrochloric Acid SCHEMBL19740396 0.90 CHRNA7 (0.81) CHRNA7HTR3A
Hydrochloric Acid SCHEMBL19740395 0.90 CHRNA7 (0.81) CHRNA7HTR3A
SCHEMBL19740432 0.86 CHRNA7 (1.00) CHRNA7HTR3A
SCHEMBL17843151 0.86 CHRNA7 (1.00) CHRNA7HTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3233087-B1 GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTORS AXOVANT SCIENCES GMBH (DE) 2019-10-02 — — EP disclosed
US-10183938-B2 Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptors AXOVANT SCIENCES GMBH (CH) 2019-01-22 — — US disclosed
US-20170369486-A1 GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTONIC ACETYLCHOLINE RECEPTORS AXOVANT SCIENCES GMBH (CH) 2017-12-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10183938-B2 Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptors CHRNA7, CHRNA6, CHRNA5 CHRNA7 1/4885HTR3A 626/4885
US-20170369486-A1 GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTONIC ACETYLCHOLINE RECEPTORS CHRNA7, CHRNA6, CHRNA5 CHRNA7 1/4885HTR3A 649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback